19th Annual Non-Dilutive Funding Summit
The 19th Non-Dilutive Funding Summit brought together hundreds of life science industry leaders with representatives from some of the leading funding agencies including ARPA-H, SEED, NINDS, NHLBI, NIMHD, NCI and more, giving attendees the opportunity to learn more in-depth about what non-dilutive funding opportunities are available and relevant for their R&D directly from the funding agencies.
Additionally, the 2023 FreeMind Elite honorees from AmplifiDx, Sapience Therapeutics, Marker Therapeutics, and Vincere Biosciences took to the stage to present about their compies research and pipelines.
This free summit is hosted by the FreeMind Group. FreeMind helps companies secure non-dilutive funding for life science R&D and wins over $100 million each year for clients. Follow us on LinkedIn or get our newsletter for news about non-dilutive funding opportunities, announcements about conferences with the best partnering, and discounts for those conferences. The 20th Non-Dilutive Funding Summit will be January 8, 2025.
“Funding and Commercialization Resources for Cancer Technologies”
National Cancer Institute (NCI)
The National Cancer Institute (NCI) is a prominent agency with the United States National Institutes of Health (NIH) that is primarily focused on cancer research, prevention, and treatment. NCI conducts research, clinical trials, and population studies to better understand cancer, develop prevention strategies, and advance treatment options. NCI administers substantial funding programs, supporting innovative research projects and breakthroughs in the fight against cancer.
Brittany Connors
Director of Investor Relations, NCI
Brittany Connors serves as the Director of Investor Relations at the National Cancer Institute Small Business Innovation Research Development Center (NCI SBIR). NCI SBIR provides federal research and development funding and commercialization resources to more than 400 small businesses developing novel technologies to prevent, diagnose, and treat cancer each year. She has worked at NCI SBIR in various roles since 2013, playing a major role in the center’s Investor Initiatives program. She has maintained a vast network and recruits more than 70 industry-leading investors and strategics annually to review the NCI SBIR portfolio and to select companies to attend and pitch at industry events across the country including RESI, Biotech Showcase, BIO, PMWC, and more.
